A new COVID-19 vaccine is on its way to hit the market. Designed by the French pharmaceutical company Valneva, this vaccine is currently working on its phase 3 trial and is expected to be completed by autumn of 2021. This vaccine is catching attention as it uses the traditional vaccine technology, which is said to create a stronger immune response to the coronavirus. Because it creates a traditional immune response, it is expected to be more effective against variants - some scientists even calling it "variant proof."
This vaccine technology is similar to those against poliovirus and the yearly flu vaccine - essentially using an inactivated version of the virus. Valneva has recruited a group from the UK for the clinical trial and has so far seen no serious or concerning side effects. Countries including France, the UK, and Australia have already shown serious interest in preordering this new vaccine.
Image Credit: Valneva
What Makes This Trend Stand Out
- Traditional Vaccine Technology
- The use of traditional vaccine technology presents an opportunity to create more effective vaccines against COVID-19 variants.
- Phase 3 Clinical Trials
- Pharmaceutical companies can take advantage of phase 3 clinical trials to test the safety and effectiveness of their COVID-19 vaccines.
- Preorder Vaccine Demand
- The high demand for preordering new vaccines presents an opportunity for pharmaceutical companies to capitalize on this market trend.
Sectors Adopting This
- Pharmaceutical
- Pharmaceutical companies can use traditional vaccine technology to create more effective COVID-19 vaccines and capitalize on the high demand for preordering.
- Medical Research
- Medical research firms can take advantage of phase 3 clinical trials to test the safety and effectiveness of new COVID-19 vaccines, like the one developed by Valneva.
- Public Health
- Public health organizations can work with pharmaceutical companies to ensure widespread distribution and uptake of new COVID-19 vaccines, including those using traditional vaccine technology.
